Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
Randomized Phase 3 Trial for Patients With AML in CR2 Comparing Total Body Irradiation (TBI) With 8Gy/Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
Sponsor: Charite University, Berlin, Germany
Terminated
insufficient patient recruitement
Listed as NCT00125606, this PHASE3 trial focuses on Acute Myeloid Leukemia and remains terminated or withdrawn. Sponsored by Charite University, Berlin, Germany, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Dec 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
- Deutsche Klinik fuer Diagnostik
- Hannover Medical School
- Johann Wolfgang Goethe University Hospital
- Ludwig-Maximilians - University of Munich
- Philipps University Marburg
- Technische Universität Dresden
- University Hospital Muenster
- University Hospital, Essen
- Universitätsklinikum Hamburg-Eppendorf
For direct contact, visit the study record on ClinicalTrials.gov .